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Abstract
Purpose N-Methoxybenzyls, a group of toxic phenylethylamine derivatives of the 2C family compounds, are a new class of 
potent serotonin 5-HT2A receptor agonist hallucinogens with potential harmful effects. This study summarizes current state 
of knowledge of one of the most dangerous representative of this group—N-(2-methoxybenzyl)-2,5-dimethoxy-4-chloro-
phenethylamine (25C-NBOMe). Due to hallucinogenic properties similar to those observe after lysergic acid diethylamide 
(LSD) usage (altered thoughts, feelings, and awareness of one’s surroundings), this compound is very attractive to halluci-
nogenic substances users.
Methods An exhaustive literature search was carried out in PubMed, Google Scholar and other biomedical data bases without 
limiting period, to identify relevant articles.
Results Despite frequent recreational use, knowledge about the 25C-NBOMe action and toxic and fatal consequences is still 
very limited. Most data on this drug come from clinical reports, from cases of acute fatal and non-fatal intoxications. Some 
animal and in vitro studies indicated a route of metabolism of the drug in the body. The drug and its metabolites were also 
detected in human blood and urine using combinations of chromatographic separation and mass spectrometry detection.
Conclusions Overall, findings show that 25C-NBOMe is a powerful hallucinogen. Easy online availability, low prize and the 
lack of knowledge of 25C-NBOMe makes this substance potentially very dangerous to its users. Thus, further investigation 
on the mechanism of action, chemical, pharmacological and toxicological properties is needed to evaluate 25C-NBOMe 
potential harmful effects.
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Introduction
According to the European Drug Reports from last years, 
the use of novel psychoactive substances (NPS) popularly 
known as legal highs, designer drugs or research chemi-
cals, rapidly increased among young people [1]. N-Meth-
oxybenzyls (NBOMes) are a new group of toxic pheny-
lethylamine derivatives of the 2C family compounds with 
N-2-methoxy-benzyl substituted by the methoxy group at 
the 2- and 5-positions and a halogen atom attached to C4 of 
the phenyl ring. Low prize on the market and an easy access 
via the internet caused that NBOMes are potentially very 
dangerous agents; however, their pharmacological proper-
ties, mechanism of action, metabolism, and toxicity have not 
been yet fully recognised. It is know that NBOMes potently 
interact with serotonin 5-HT2A, 5-HT2B, 5-HT2C receptors, 
adrenergic α1 receptors and dopaminergic  D1 receptors, 
but have lower affinity at 5-HT1A receptor [2]. All agents 
of the NBOMes group exhibit low nanomolar affinity for 
5-HT2A receptors which is higher in comparison to other 
2C compounds [3]. This affinity correlates with NBOMes 
hallucinogenic potency in humans [4]. Moreover, 5-HT1A 
receptor stimulation has been hypothesized to counteract 
hallucinogenic activity and in consequence a lower 5-HT1A 
receptor stimulation for the NBOMes compounds may fur-
ther enhance their hallucinogenic properties [5].
25C-NBOMe [N-(2-methoxybenzyl)-2, 5-dimethoxy-
4-chlorophenethylamine] known also as NBOMe-2C-C, 
2C-C-NBOMe C-Boom, 25C, legal acid, NBomb, NE-
BOME, Pandora, Dime, NBOMe-2C-C, BOM, 2-C-Cor, 
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Cimbi-82 began to be sold via online sites in 2010 but its 
use was not reported in the scientific literature until 2011 
[6]. The effect of 25C-NBOMe usage is characterized by 
various psychiatric and physiological effects like hallucina-
tion [7], violent agitation, euphoria, insomnia, rhabdomy-
olysis and kidney injury. 25C-NBOMe has effects similar to 
those of lysergic acid diethylamide (LSD) and according to 
some media reports LSD users may often unwittingly ingest 
25C-NBOMe, instead of LSD [8].
The present study provides a brief review on available 
data about 25C-NBOMe chemical structure and properties, 
widely understood biological effects of its intake and ana-
lytical methods used for identification of this compounds 
in humans.
Chemical characterisation
Published data about chemical characterisation of 
25C-NBOMe is very limited so far. 25C-NBOMe contains 
the substructure of 4-chloro-2, 5-dimethoxyphenethyl-
amine (2C–C), substituted with the N-(2-methoxy) benzyl 
group (Fig. 1). The molecular formula of 25C-NBOMe is 
 C18H22ClNO3 and the molecular weight of free base is 335.8. 
25C-NBOMe does not have chiral centres and thus does not 
form stereoisomers [9].
There are several chemical names for 25C-NBOMe, 
the  most  commonly  use  a re  2 - (4-ch loro-2 , 
5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine, 
2-(4-chloro-2, 5-dimethoxyphenyl)-N-(2-methoxybenzyl) 
ethan-1-amine, Cimbi-82 (11C radiolabelled for PET 
scanning)—Center for Integrated Molecular Brain Imaging 
(CIMBI).
The synthesis of 25C-NBOMe, schematically illustrated 
in Fig. 2, follows the process described by Heim in 2003 
[10].
Pharmacological characterisation
25C-NBOMe acts as a potent partial agonist for the 5-HT2A 
serotonin receptor with binding affinity of 2.89 ± 1.05 nM 
in vitro [11]. Stimulation of the 5-HT2A receptors is essential 
for the hallucinogenic effects of drugs [12, 13]. Limited stud-
ies using animal experiments have shown that 25C-NBOMe 
induced a head twitch response of a behavioural marker of 
hallucinogenic effects induced by activation of the 5-HTA2 
receptor [14]. In the work of Xu et al. 25C-NBOMe was 
tested in vitro against neuroblastoma human cell line SH-
SY5Y, PC12-cell line derived from a pheochromocytoma 
of the rat adrenal medulla, and a mouse neuron-like dopa-
minergic cell line SN4741 to evaluate neurotoxic effects 
of the drug. The cells were treated with 25C-NBOMe 
(25–400 μM) and measured after 24 h by the in vitro cyto-
toxicity assay with MTT dye (MTT) a colorimetric assay 
for assessing cell metabolic activity [15]. It was found that 
concentrations above 100 μM of 25C-NBOMe significantly 
decreased cell viability in all three cell lines. An increased 
apoptotic process was observed only for SN4741 cells sug-
gesting preferentially potent neurotoxicity of 25C-NBOMe 
in the dopamine cells. Xu and co-workers also showed that 
25C-NBOMe concentration of 50 µM inhibited activities 
of phosphorylated Akt-kinase (pAkt) and pSer9 (GSK3b 
Antibody)-Glycogen synthase kinase 3 beta (GSK3β) and 
enhanced expression of pERK. Thus 25C-NBOMe may 
produce in vitro neurotoxicity via a PI3-K/Akt pathway 
inhibition and the activation of the extracellular signal-reg-
ulated kinase (ERK) signaling pathway cascade by agonist 
action on 5-HT2A ERK [15, 16]. Gatch and co-workers have 
reported in their work that administration of 25C-NBOMe 
(0.5, 1, 2.5, and 5  mg/kg) resulted in time- and dose-
dependent locomotor activity depression with depressant 
effects occurred within 10 min after injection which lasted Fig. 1  Chemical structure of 25C-NBOMe
Fig. 2  Schematic of the 
25I-NBOMe synthesis process
492 Forensic Toxicology (2020) 38:490–495
1 3
30–60 min [17]. Moreover, 25C-NBOMe (0.5, 1, 2.5, and 
5 mg/kg) generated substantial fluctuations in drug-appro-
priate responding with maximum effects of approaching 80% 
drug-appropriate responding. To our best knowledge there 
is no data about the abuse potential of 25C-NBOMe neither 
in animals or in humans. Importantly, these novel halluci-
nogen is extremely potent and psychoactive at microgram 
doses when taken buccally, administrated sublingually and 
insufflated.
Wohlfarth et al. have demonstrated in in vitro and in vivo 
studies that 25C‐NBOMe is metabolized by O‐demethyla-
tion, O‐di‐demethylation and hydroxylation. According 
to authors, all methoxy groups in 25C-NBOMe could be 
demethylated with hydroxylation preferably occurred at 
the NBOMe ring [18]. Furthermore, phase I metabolites 
were extensively conjugated with glucuronic acid and sul-
fate in human urine [18]. Caspara et al., have investigated 
the metabolism of 25C-NBOMe in rats and humans using 
liquid chromatography coupled to mass spectrometry high-
resolution [19]. 25C-NBOMe was metabolized by O-dem-
ethylation, O, O-bis-demethylation and hydroxylation. Sixty 
nine phase I metabolites were identified. Most metabolites 
were common for all investigated spieces but N-dealkylated, 
O-demethylated metabolites and various isomers of O, 
O-bis-demethyl-hydroxy metabolites were detected in rat 
urine only [19].
Effects of 25C‑NBOMe intake
According to internet web sites dedicated to the hallu-
cinogenic substances users—Erowid, 25-NBOMe acts 
as an active hallucinogen agent at a dose of 200–500 µg 
when insufflated. The users described effects as light for 
50–200 μg, mild for 200–350 μg, strong for 350–700 μg, and 
very strong after intake of higher doses. Three hundred to six 
hundred µg doses taken buccally are only one third potency 
of LSD (2C-C-NBOMe Dose–Erowid). When administered 
sublingually, the threshold for the onset of hallucinogenic 
effects reportedly is about 100–250 μg, with mild, strong, 
and very strong effects after 250–450, 450–800, and over 
800 μg, respectively [20, 21]. Overdose of 25C-NBOMe 
have been linked to hospitalizations due to multi-organ fail-
ures and deaths [22, 23].
Applied analytical methods
Non-fatal case studies have reported various psychiatric 
and physiological effects of 25C-NBOMe intake, like hal-
lucination [7], violent agitation, euphoria, insomnia, rhab-
domyolysis and kidney injury, tachycardia, hypertension, 
seizures, hyperpyrexia [24]. Zygowiec et al. have described 
a case of a 27-year-old male with confirmed ingestion of 
a psychoactive substance. High-performance liquid chro-
matography-tandem mass spectrometry (HPLC–MS/MS) 
detected 25C-NBOMe, 25H-NBOMe and 25B-NBOMe in 
blood samples with concentrations above the 0.50 ng/mL 
reporting limits [25]. Rajotte et al. have described toxico-
logical analyses including 25C-NBOMe in a drug-impaired 
driver. Gas chromatography-mass spectrometry (GC–MS) 
showed a mass spectral identification of this agent [26]. First 
the driver urine sample was analysed by two immunoassay 
panels screened for low concentration of psychoactive sub-
stances. GC–MS was performed for beta-hydroxybutyrate 
(20 mg/L) and gamma-hydroxybutyrate (2.5 mg/L) analy-
sis. The only positive drug finding from these analyses was 
an NBOMe compound. Retrospectively, the detected com-
pound was identified as 25C-NBOMe [26]. A young male 
died in a hospital approximately 12 h after the use of the 
psychoactive substance. The death was preceded by hallu-
cinations and convulsions. A hospital examination showed 
a wild spectrum of physiological effects. 25C-NBOMe and 
its demethylated and glucuronidated metabolites were identi-
fied in urine and whole blood using ultra-performance liquid 
chromatography with high-resolution time-of-flight mass 
spectrometry (UPLC–HRTOF–MS) and ultra-performance 
liquid chromatography with tandem mass spectrometry 
(UPLC–MS/MS) [27]. The limit of detection and lower limit 
of quantification were 0.02 mg/kg and 0.08 mg/kg, respec-
tively [27]. In turn Murini and co-workers have reported a 
case of a teenager male who was found dead in a waterway 
after jumping off into water stream [28]. The death occurred 
by drowning but to evaluate the potential role of psycho-
active substances the toxicological exams were performed. 
Peripheral and central blood as well urine samples were col-
lected and analysed by liquid chromatography tandem mass 
spectrometric (LC–MS/MS). The method was linear over 
the range from 0.1 to 5.0 ng/mL. Accuracy and imprecision 
were measured, calibration curve used in this at two different 
quality controls (0.2 and 1.0 ng/mL) and were found to be 
within the 15%. Five 25-NBOMes, including 25C-NBOMe, 
were identified in the samples [28]. An accidental death of a 
23-year-old male has been reported by Kristofic et al. A fast 
liquid chromatography quadrupole time-of-flight mass spec-
trometry (LC-QTOF-MS) with a basic solid-phase extrac-
tion was employed to isolate 25C-NBOMe, 25C-NBOH and 
2C–C from blood and urine specimens. An LC–MS/MS 
analysis exhibited the presence of 25C-NBOMe and 2C–C in 
blood and urine samples The QTOF mass spectrometer was 
operated in positive electrospray ionization mode utilizing 
MSE acquisition, which permits simultaneous acquisition 
under low collision energy and high collision energy func-
tions [29]. Similarly, Soh and Ellion have showed two fatal 
cases in which a possible metabolite of 25C-NBOMe was 
detected in blood and urine [30]. Detection and identification 
493Forensic Toxicology (2020) 38:490–495 
1 3
Table 1  Effect of 25C-NBOMe intake, analytical methods and the result of the real sample analysis
The effect of 25-NBOMe intake
 Psychiatric effects
  Positive effects: mental stimulation, physical stimulation, creative thinking, mood lift, open and closed eye visuals, increased awareness, life-
changing spiritual experiences, euphoria [8]
  Negative effects: general change in consciousness, pupil dilation, difficulty focusing, unusual body sensations, change in perception of time, 
slight increase in heart rate, hot flushes and/or cold chills [8]
  Neutral effects: nausea, insomnia, paranoia, fear, panic, unwanted and overwhelming feelings, unwanted life-changing spiritual experiences 
[8]
 Physiological effects
  Organ injuries: rhabdomyolysis and kidney injury [24]
  Cardiological effects: tachycardia, hypertension, seizures, hyperpyrexia [24]
  Other: dry mucous membranes and skin [25], bleeding from all mucosa, respiratory and metabolic acidosis, high lactic acid, anuria, hyper-
thermia, hyperkalaemia [27]
Analytical methods
 High performance liquid chromatography: tandem mass spectrometry (HPLC–MS/MS)
 Gas chromatography: mass spectrometry (GC–MS)
 Ultra: performance liquid chromatography with high-resolution time-of-flight mass spectrometry (UPLC–HRTOF–MS)
 Ultra-performance liquid chromatography with tandem mass spectrometry (UPLC–MS/MS)
 Liquid chromatography tandem mass spectrometric (LC–MS/MS)
 Fast liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS)
 Ultra high performance liquid chromatography with high mass accuracy quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS)
 High performance liquid chromatography with diode-array detection (HPLC–DAD)
 Liquid chromatography with mass spectrometry (LC–MS)
 Fourier-transform infrared spectrometry (FTIR)
 Nuclear magnetic resonance spectroscopy (NMR)
Result of the real sample analysis (25-NBOMe examples concentration in biological samples by different analytical methods)
 Blood samples
  Peripheral blood: 2.80 ng/mL by LC–MS/MS [28]
  Central blood: 1.43 ng/mL by LC–MS/MS [28]
  Post-mortem peripheral blood: 0.60 mg/kg by UPLC-HRTOF-MS and UPLC–MS/MS [27]
  Ante-mortem whole blood: 0.81 mg/kg by UPLC–HRTOF–MS and UPLC–MS/MS [27]
 Urine samples
  Urine: 0.94 ng/mL by LC–MS/MS [28]
 Liver
  Liver: 0.82 mg/kg by UPLC–HRTOF–MS and UPLC–MS/MS [27]
  Liver: 15.2 ng/g by LC-QTOF-MS and LC-MS/MS [29]
 Gastric content
  Gastric sample: 0.32 mg by UPLC–HRTOF–MS and UPLC–MS/MS [27]
  Gastric contents: 30.2 μg total in 100 mL by LC-QTOF-MS and LC-MS/MS [29]
 Vitreous humour samples
  Vitreous humor: 0.33 mg/kg UPLC–HRTOF–MS and UPLC–MS/MS [27]
 Brain
  Brain: 19.1 ng/g by LC-QTOF-MS and LC-MS/MS [29]
 Spleen
  Spleen: 27.1 ng/g by LC-QTOF-MS and LC-MS/MS [29]
 Lungs
  Lung: 25.2 ng/g by LC-QTOF-MS and LC-MS/MS [29]
 Kidneys
  Kidney: 25.1 ng/g by LC-QTOF-MS and LC-MS/MS [29]
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of 25C-NBOMe were carried out using high-performance 
liquid chromatography with diode-array detection (HPLC-
DAD), LC–MS/MS and ultra high performance liquid chro-
matography with high mass accuracy quadrupole time-of-
flight mass spectrometry (UHPLC-Q-TOF-MS) [30].
Till now 25C-NBOMe was identified in ante-mortem 
and post-mortem samples of whole blood, liver, urine, gas-
tric content, and vitreous humour samples [27]. Zuba and 
co-workers have proposed analytical procedures for the 
identification of 25C-NBOMe in blotter papers originating 
from the drug market [20]. Several analytical techniques 
were applied to detect this drug such as GC–MS with and 
without derivatization with trifluoroacetic anhydride, liquid 
chromatography with mass spectrometry (LC–MS), Fourier-
transform infrared spectrometry (FTIR) and nuclear mag-
netic resonance (NMR) spectroscopy [31]. The dominant 
ions, representatives of 25-NBOMe series in GC–MS spec-
trum of 25C-NBOMe were observed at m/z = 121,150 and 91 
[31]. The FTIR spectrum of the sample was recorded in the 
600–4000 cm−1 rang. The strong peaks assigned to C–O–C 
(25-NBOMe series, are characterized by the asymmetric 
C–O–C stretch vibrations near) vibrations were observed at 
1036 cm−1, 1215 cm-1 and 1252 cm−1 [31]. In case of NMR 
spectroscopy, the signals in the 1H and 13C spectra were 
assigned on the basis of one- and two-dimensional homo- 
and heteronuclear experiments [20].
The table below shows the effect of 25C-NBOMe intake, 
analytical methods and the result of the real sample analysis 
(Table 1).
Conclusions
The case studies clearly indicated that the exposure on 
25C-NBOMe leads to fatal and non-fatal intoxication of its 
users and it can be unwittingly ingest instead of LSD. How-
ever, a number of NBOMe-related intoxications and deaths 
could be underestimated due to the lack of proper and sensi-
tive analytical methods. Despite the fact of recognised fatal 
cases there is still a lack of experimental studies explaining 
the mechanism of its action and providing information about 
pharmacological properties and toxicity. Although adverse 
effects of 25C-NBOMe are known, long-lasting and chroni-
cal usage effects have not been recognised so far. To over-
come these issues and to develop analytical procedures of 
identification of this toxic agent further extensive studies on 
the 25C-NBOMe action are urgently needed.
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